Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
By Malcolm J. Moore, David Goldstein, J. Hamm, A. Figer, Joel R Hecht, Steven Gallinger, H. Au, Pawel Murawa, D. Walde, Robert A. Wolff and 7 more. Journal of Clinical Oncology, 2007
802 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/6c92020dc91a0b18427e42cea7756892d78f403e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “The only targeted therapy approved for the treatment of PDAC, the epidermal growth factor receptor (EGFR) inhibitor erlotinib, when used in combination with gemcitabine, extended life by a statistically significant but clinically unimpressive 12 days more than gemcitabine alone (Moore et al. 2007).”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “99) 1 [150].”